All the trading advice you’ve ever received boils down to this

All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.

Drop everything and learn about the Income Calendar now.

Robert M. Plenge net worth and biography

Robert Plenge Biography and Net Worth

EVP of Bristol-Myers Squibb

Robert Plenge, MD, PhD, is executive vice president, chief research officer and head of Research at Bristol Myers Squibb. He leads scientific activities across eleven research sites around the world all focused on transforming patients’ lives through science.

Prior to his current role, Robert served as head of Discovery & Translational Sciences at Bristol Myers Squibb, which spanned all therapeutic areas at the company. Robert joined BMS as part of the acquisition of Celgene in November 2019. At Celgene, he served as vice president, Immunology & Inflammation portfolio, Research & Early Development. Prior to joining Celgene, Robert was vice president and Head of Translational Medicine at Merck.

Robert received his MD and PhD from Case Western Reserve University and holds a BS from the University of California, San Diego. He completed his internal medicine residency as a molecular medicine fellow at the University of California, San Francisco. He served as rheumatology fellow at Brigham & Women’s Hospital and postdoctoral research fellow at the Broad Institute of MIT and Harvard. He was an assistant professor of medicine at Harvard Medical School and an associate member of the Broad Institute while practicing clinical rheumatology and running a research laboratory at Brigham & Women’s Hospital.

Robert is an author of more than 125 manuscripts published in peer-reviewed journals, and frequently posts updates to his personal blog, Plenge Gen, commenting on critical discovery moments with a focus on the resulting patient impact. He is a recipient of several academic and corporate awards and currently serves on the Board of Directors for the PhRMA Foundation.

What is Robert M. Plenge's net worth?: The estimated net worth of Robert M. Plenge is at least $336,376.56 as of August 3rd, 2023. Dr. Plenge owns 6,584 shares of Bristol-Myers Squibb stock worth more than $336,377 as of December 11th. This net worth estimate does not reflect any other investments that Dr. Plenge may own. Learn More about Robert M. Plenge's net worth.
How do I contact Robert M. Plenge?: The corporate mailing address for Dr. Plenge and other Bristol-Myers Squibb executives is 430 E. 29TH STREET 14 FLOOR, NEW YORK NY, 10016. Bristol-Myers Squibb can also be reached via phone at (212) 546-4000 and via email at [email protected]. Learn More on Robert M. Plenge's contact information.
Has Robert M. Plenge been buying or selling shares of Bristol-Myers Squibb?: Robert M. Plenge has not been actively trading shares of Bristol-Myers Squibb within the last three months. Most recently, Robert M. Plenge sold 732 shares of the business's stock in a transaction on Thursday, August 3rd. The shares were sold at an average price of $61.14, for a transaction totalling $44,754.48. Following the completion of the sale, the executive vice president now directly owns 6,584 shares of the company's stock, valued at $402,545.76. Learn More on Robert M. Plenge's trading history.
Who are Bristol-Myers Squibb's active insiders?: Bristol-Myers Squibb's insider roster includes Mark Alles (CEO), Christopher Boerner (EVP), Giovanni Caforio (CEO), Adam Dubow (SVP), Joseph Eid (SVP), John Elicker (EVP), David Elkins (CFO), Sandra Leung (EVP), Dinesh Paliwal (Director), Robert Plenge (EVP), Ann Powell (EVP), Theodore Samuels, II (Director), Karen Santiago (SVP), Louis Schmukler (EVP), Rupert Vessey (EVP), and Paul von Autenried (EVP). Learn More on Bristol-Myers Squibb's active insiders.
Are insiders buying or selling shares of Bristol-Myers Squibb?: During the last year, Bristol-Myers Squibb insiders bought shares 3 times. They purchased a total of 13,571 shares worth more than $672,994.06. During the last year, insiders at the biopharmaceutical company sold shares 5 times. They sold a total of 320,286 shares worth more than $23,276,473.35. The most recent insider tranaction occured on December, 5th when CEO Christopher S Boerner bought 2,000 shares worth more than $99,560.00. Insiders at Bristol-Myers Squibb own 0.1% of the company. Learn More about insider trades at Bristol-Myers Squibb.
Information on this page was last updated on 12/5/2023.

Robert M. Plenge Insider Trading History at Bristol-Myers Squibb

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/3/2023	Sell	732	$61.14	$44,754.48	6,584

Robert M. Plenge Buying and Selling Activity at Bristol-Myers Squibb

Bristol-Myers Squibb Company Overview

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Onureg for the treatment of adult patients with AML; Inrebic, an oral kinase inhibitor indicated for the treatment of myelofibrosis; Camzyos for the treatment of adults with symptomatic obstructive HCM to enhance functional capacity and symptoms; Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane, a protein-bound chemotherapy product. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Today's Range

Now: $51.09

$50.27

$51.14

50 Day Range

MA: $52.75

$48.48

$57.89

2 Week Range

Now: $51.09

$48.25

$79.36

Volume

18,429,926 shs

Average Volume

9,970,625 shs

Market Capitalization

$103.96 billion

P/E Ratio

12.97

Dividend Yield

4.53%

Beta

0.34

Is the Biden Administration Ultimately Good for Gold - and Gold Royalties?

From Edge On The Street | Ad

With spending financed by deficits, increased public debt, and global uncertainty, it's no wonder many gold analysts expect prices to break all-time highs in '24. It also has investors turning to a unique "Gold Royalty" strategy offering the potential of rising gold prices without the operational risks of mining or physical gold storage.

See why this gold royalty alternative has so much